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Summary: Tissue polypeptide antigen, measured by both a polyclonal antibody (TPA IRMA Prolifigen®) and a
monoclonal antibody prototype kit (TPA-M IRMA Prolifigen®), and the tissue polypeptide specific antigen were
evaluated. The markers were measured in 266 serum samples and in 291 tumour cytosols from patients with primary
breast cancer. The three markers were available in matched pairs of both serum and cytosol from the same patient
in 144 cases.
Diagnostic sensitivity of serum levels of the three markers was not significantly different when using cut-off values
calculated on the basis of healthy subjects.
In the cytosol, tissue polypeptide antigen (TPA IRMA), tissue polypeptide antigen (TPA-M IRMA) and tissue
polypeptide specific antigen were significantly correlated with steroid receptor Status, while their serum levels
were not.
Cytosol and serum levels of the three markers were not significantly associated. All three were significantly corre-
lated both in serum and in cytosol. The association was closer between tissue polypeptide antigen (TPA IRMA)
and tissue polypeptide antigen (TPA-M IRMA) than between each of these two markers and tissue polypeptide
specific antigen.
From these findings we dfäw the following conclusions:
1. Tissue polypeptide specific antigen (TPA IRMA) and tissue polypeptide antigen (TPA-M IRMA) probably
provide superimposable information both in serum and in cytosol;
2. Tissue polypeptide specific antigen and tissue polypeptide antigen (TPA IRMA) or tissue polypeptide antigen
(TPA^M IRMA), although closely associated, probably measure in part different cytokeratins. Therefore, they should
not be considered interchangeable in individual patients;
3. The determination of the markers in serum and in cytosol provides diiferent information concerning the tumour
phenotype.
Introduction
Keratin is one of the five classes of intermediate fila- first is represented by polypeptides with a relatively high
ments that have a major role äs a componeht of the cy- molecular mass and more acidic pl (types l to 8), the
tosleeleton of epithelial tissues (1). second by those with a relatively low molecular mass
The keratin filament family consists of 20 distinct poly- and a more basic pl (types 12 to 20) (2). Usually, a basic
peptides that can be subdivided into 2 major groups: the and an acidic polypeptide are associated in a heterodim-
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eric keratin filament (3). Cytokeratins 8/18 and 8/19 are
frequently expressed in several simple epithelia and in
the malignancies that are derived from these (4-6).
Although cytokeratins are virtually insoluble (7), several
soluble fragments are released by the tissue, so that it is
possible to assay cytokeratin-related biochemical indica-
tors in body fluids.
The first marker of this group was identified and de-
scribed by Björklund & Björklund and named tissue
polypeptide antigen (TPA IRMA) (8). Tissue polypep-
tide antigen (TPA IRMA) was elevated in the blood of
patients affected by several types of tumours and was
related to poor prognosis in some malignancies (8—13).
In breast cancer, higher serum tissue polypeptide antigen
(TPA IRMA) levels were correlated with a poor progno-
sis (13). Conversely, a high cytosol tissue polypeptide
antigen (TPA IRMA) level was shown to be a powerful,
independent, favourable prognostic indicator (14—16).
New Information was obtained with the aid of hybri-
doma technology, which led to the development of sev^
eral monoclonal antibodies against tissue polypeptide
antigen. They were used both for molecular studies (17,
18) and to devise different assay kits to measure tissue
polypeptide antigen in body fluids. Biochemical studies
demonstrated that the different monoclonal antibodies
used in different commercial assay kits recognize the
cytokeratins 8, 18 and 19 in a different manner (18). A
monoclonal antibody assay kit, named tissue polypep-
tide specific antigen, was devised by BEKI Diagnostic.
It has been claimed that the antibody of the tissue poly-
peptide specific antigen assay kit recognizes a specific
tissue polypeptide antigen epitope (M3) that is probably
different from cytokeratins (19, 20).
However, recent work by Bodenmüller et al. (18) has
shown that antibodies used in the tissue polypeptide an-
tigen (TPA IRMA) assay strongly react with cytokera-
tins 8 and 19, while tissue polypeptide specific antigen
antibody strongly reacts with cytokeratin 18, but very
weakly with cytokeratin 8 in the immunoblot assay. As
a consequence, tissue polypeptide antigen (TPA IRMA)
antibodies recognize the combination cytokeratin 8/18
and cytokeratin 8/19, while tissue polypeptide specific
antigen antibodies preferably recognize the combination
cytokeratin 8/18. From these data it can be expected that
tissue polypeptide antigen (TPA IRMA) assay recog-
nizes a broader spectrum of patients than tissue polypep-
tide specific antigen, äs cytokeratin 18 can also be asso-
ciated with other acidic keratins. In accordance with
these fmdings, Stieber et al. (21) have reported clearly
different sensitivity values of tissue polypeptide antigen
(TPA IRMA) and tissue polypeptide specific antigen äs-
says in patients with lung cancer.
In the present investigation we evaluated the tissue poly-
peptide antigen (TPA IRMA) assay, a new monoclonal
antibody-based tissue polypeptide antigen assay ( -
IRMA), and tissue polypeptide specific antigen in
serum and cytosol from primary breast cancer, address-
ing the following items: . f
1. to evaluate the association between the markers and
other disease indicators (tumour size, nodal Status, histo-
logical type, tumour grade, steroid receptors);
2. to evaluate whether the markers show similar or dif-
ferent association patterns with other disease jjidicators
when measured in serum and in cytosol;
3. to evaluate the association among the markers, in or-
der to assess whether they can be expected to provide
redundant or additional Information.
Materials and Methods
Serum and tumour tissue samples were collected from 342 patients
with primary breast cancer. Serum samples from 76 apparently
healthy subjects were also evaluated. Statistical evaluation was re-
stricted to cases in which all the three markers had been assayed,
i.e. 266 for serum, 291 for cytosol and 144 for matched pairs of
both serum and cytosol from the sarne patient. Serum samples were
collected on the day of the Operation before the administration of
any drug. Tissue samples of primary breast cancer were collected
freshly from the operating room, kept on ice and stored within 30
minutes in liquid nitrogen. Frozen tissue samples were pulverized
using a microdismembrator and suspended in phosphate buffer (tis-
sue/buffer ratio ranging frorn l : 8 to l : 20). The homogenate was
then centrifuged for l hour at 100 000 g and the supernatant (cyto-
sol) used for biochemical assays.
Tissue polypeptide antigen was measured using both the polyclonal
(TPA IRMA Prolifigen®) and a monoclonal antibody-based two-
site sandwich solid phase immunoradiometric assay kit (TPA-M
IRMA Prolifigen®), kindly provided by Sangtec Medical, Bromma,
Sweden. The TPA-M IRMA Prolifigen® used at the time of the
investigation was still a prototype version.
Tissue polypeptide specific antigen (TPS) was measured by the
two-site sandwich immunpradiometric assay kindly supplied by
BEKI Diagnostic (Bromma, Sweden). The assays were carried out
according to the manufacturer's instructions. The performance
characteristics of the assays were evaluated according to Standard
criteria (22,23). Both inter* and intra^assay precision were assessed
by measuring pools of human sera at low, intermediate and high
antigen concentrations. The sensitivity was expressed äs the'dose
corresponding tö the counts per miriute resülting from the mean
plus 3 Standard deviations of the "0" Standard calibrator. The accu-
racy was evaluated with the dilution test, which was carried out by
using phosphate buffer containirig 3 g/l of bovine serum alburnm.
This buffer had been previously validated for the tissue polypeptide
antigen (TPA IRMA) assay in cytosol samples (14). The resülts
of the evaluation of performance characteristics are summarized
in table 1.
Oestrogen and progesterone receptors were measured using a
radioligand binding assay set up according to the EORT C criteria
(24). The conventional value of 10 fmol/mg of cytosol protein was
used for both oestrogen receptors and progesterone receptors to
categorize tumour samples äs positjve or negative.
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Tab. l Performance characteristics of tissue polypeptide antigen (TPA IRMA), tissue polypeptide
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The cytosol protein concentration was measured using the Coomas-
sie Brilliant Blue Colorimetric assay (Βίο-Rad Laboratories ECS
Division, Anaheim, CA) (25).
Statistical analysis was carried out using the Kruskal-Wallis test
and linear regression analysis.
Results
Both serum and cytosol levels of the three markers are
summarized in table 2. The diagnostic sensitivity of se-
rum marker levels was evaluated at 95% and 99% speci-
ficity with reference to a group of 76 healthy subjects.
The figures were respectively 25.3% and 17.4% for tis-
sue polypeptide antigen (TPA IRMA), 25.9% and 18.4%
for tissue polypeptide antigen (TPA-M IRMA) and
28.4% and 18.3% for tissue polypeptide specific anti-
gen. Serum concentrations of tissue polypeptide antigen
(TPA IRMA) and tissue polypeptide specific antigen
showed similar values, while tissue polypeptide antigen
(TPA-M IRMA) was lower. In the cytosol, tissue poly-
peptide antigen (TPA-M IRMA) showed the highest
concentration and tissue polypeptide specific antigen the
lowest, while tissue polypeptide antigen (TPA IRMA)
presented intermediate levels. These comparisons should
however be considered aitifaptual and poorly informa-
tive, since the marker concentrations are expressed in
arbitrary units. Of m^jor interest are the ratios between
serum and cytosol levels for each marker, since in this
case the absolute numerical value of the eoncentrations
is not relevant. The concentrations of the three markers
were higher in cytosol than in serum. However, the cyto-
sol to serum ratip was significantly (p < 0.01) different
between the three markers, being 22 for tissue polypep-
tide antigen (TPA-M IRMA), 8 for tissue polypeptide
antigen (TPA IRMA) and 4 for tissue polypeptide spe-
cific antigen.
Relationship with other quantities and
indicators
Serum levels of tissue polypeptide antigen (TPA-M
IRMA) were significantly higher in N H- than in N—
cases (Kruskal-Wallis test p = 0.038) and tended to be
higher in larger tumours (0 > 2 cm) than in smaller
ones (0 < 2 cm) (Kruskal-Wallis test p = 0.054). Al-
though a similar trend was found for tissue polypeptide
antigen (TPA IRMA) and tissue polypeptide specific an-
tigen in relation to tumour size, differences were not
significant in the case of these two latter markers. Also,
tissue polypeptide antigen (TPA IRMA) and tissue poly-
peptide specific antigen showed no differences at all be-
tween N+ and N— cases.
Cytosol levels of the three markers did not show any
relation with either nodal Status or tumour size.
Serum and cytosol levels of the three markers did not
show significant variations related to histological type
or tumour grade (data not shown).
In general, the cytosol levels of the three markers were
higher in cases in which oestrogen receptors and proges-
terone receptors were expressed (fig. 1), while their se-
rum levels were not associated with steroid receptor
Status. Cytosol tissue polypeptide antigen (TPA IRMA)
was significantly higher in oestrogen receptor positive
tumours than in oestrogen receptor negative tumours,
and higher in progesterone receptor positive tumours
than in progesterone receptor negative tumours
(Kruskal-Wallis test p < 0.0001 for both). The same be-
haviour, although at a lower significance level for pro-
gesterone receptor, was found for tissue polypeptide an-
tigen (TPA-M IRMA) (Kruskal-Wallis test p < 0,0001
for oestrogen receptors, p = 0.0120 for progesterone re-
ceptors) and tissue polypeptide specific antigen
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Tab. 2 Tissue polypeptide antigen (TPA IRMA), tissue polypeptide antigen (TPA-M IRMA) and
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Oestrogen Progesterone Oestrogen Progesterone Oestrogen Progesterone
receptor receptor receptor receptor receptor receptor
+ - + . + . + „ + , + _
Tissue polypeptide antigen Tissue polypeptide antigen Tissue polypeptide
(monoclonäl antibody kit) specific antigen
Fig. l Relationship between the marker cytosol levels and steroid
receptor Status. Vertical bars represent the interquartile ränge of
tumour marker levels. The horizontal line is taken äs the median
value. The positive/negative threshold level was 10 fmol/mg of
cytosol protein for both oestrogen and progesterone receptors. The
marker levels were normalized with reference to the median value
of each rnarker.
(Kruskal-Wallis test p < 0.0001 for oestrogen receptors, by the linear regression analysis between the logarithms
p = 0.0011 for progesterone receptors). The association* of the concentrations of both tumour markers and
between the markers and receptor Status was confirmed oestrogen reeeptor or progeßterone reeeptor (tab. 3).
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Tab. 3 Association between the cytosol levels of tumor markers
and receptor Status. Results of linear regression analysis between

































These findings confirm a preliminary report of our
group, in which we found a significant association be-
tween oestrogen receptor and cytosol tissue polypeptide
antigen (26). They are also in agreement with previous
findings of our group that demonstrate a significant as-
sociation between higher tissue polypeptide antigen cy-
tosol levels and a better prognosis (14—16).
Association among the three markers
The three markers were significantly associated both in
serum (flg. 2) and in the cytosol (fig. 3). The association
pattern was similar using both data and logarithm of
data, the latter being shown in the figures. The marker
levels were more closely associated in the cytosol than
in serum. These findings could suggest either differences
of distribution and metabolism, or a different release by
the tumour of the three markers, and they support a pos-
sible difference among the mplecules recognized by the
three different assay kits.
Relationship between cytosol and serum
Figure 4 shows the regression analysis between serum
and cytosol levels öf the three markers. According to the
data, äs well äs the logarithms of data, the levels of the
marker in the two compartments were not associated,
although a non-significant trend toward a» negative asso-
ciation between serum and cytosol tissue polypeptide
antigen (TPA IRMA) was found, These findings clearly
indicate that the marker serurn level is probably affected
by several variables other than produetion and release
by the turnöur, and emphasize that it is difficult to pfe-
dict the usefulness of the determinätion of markers in
the blood from their concentration in the cytosol. On the
other band, the determinätion of the marker in the two
biological fluids could possibly provide different Infor-
mation.
Discussion
The number of tumour markers used in the clinical prac-
tice should be restricted, in order to avoid redundant
Information and to reduce unnecessary costs. This prob-
lem arises when several tumour markers belonging to
the sarne molecular family are available, äs in the case
of cytokeratin related biochemical indicators, for which
several commercially available kits have been recently
developed. Indeed, different assay kits could provide
different clinical Information in some individual pa-
tients. An unanswered question is whether this anecdotal
benefit may justify the cost of performing routinely a
panel of cytokeratin family markers in any patient. The
same item has been raised in the case of mucin markers
for breast cancer. Indeed, general consensus was reached
on the possibility of using a single mucin marker in this
latter malignancy (27).
In the case of the cytokeratin-related markers, two
diverse opinions exist. On the one hand, Björklund et
al. consider that tissue polypeptide specific antigen
recognizes an antigen associated with proliferation
which is not a cytokeratin (19, 20). Although they
admit a possible cross-reactivity of tissue polypeptide
specific antigen with cytokeratins, even with a lower
affinity, they suggest that tissue polypeptide antigen
(TPA IRMA) and tissue polypeptide specific antigen
provide different biological Information, the first being
related to cell death and the second to cell prolifera-
tion (20). On the other hand, Bodenmüller et al. de-
monstrated that the antibody used in the tissue poly-
peptide specific antigen assay kit recognizes cytokera-
tin 18, which led them to include tissue polypeptide
specific antigen among the cytokeratin family of tu-
mour markers (18). The problem should be evaluated
from the point of view of the clinical application, to
assess whether the markers provide similar or different
Information. This point is of relevance in breast can-
cer, since both serum and cytosol tissue polypeptide
antigen (TPA IRMA) levels showed a clear clinical
usefulness (10, 13-16).
Tissue polypeptide antigen and tissue polypeptide spe-
cific antigen were therefore compared in a group of pa-
tients with breast cancer, which was large enough for
statistical evaluation. Both the old polyclonal antibody-
based tissue polypeptide antigen (TPA IRMA), which
had been thoroughly studied in breast cancer, and the
more recently available monoclonal antibody-based tis-
sue polypeptide antigen (TPA-M IRMA) were assayed.
Indeed, the latter tissue polypeptide antigen (TPA-M
IRMA) assay presents two advantages in comparison to
the old one: firstly, the cytokeratins recognized by the
monoclonal antibody are well known, and secondly, the
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Fig. 2 Correlation among serum levels of the three markers (lin- Tissue polypeptide antigen (TPA IRMA) vs tissue polypeptide anti-
ear regression analysis using In of data). gen (TPA-M IRMA): y = -1.50 + 1.175x; n = 266; r = 0.788;
Linear regression analysis: p < 0.001.
Tissue polypeptide antigen (TPA IRMA) vs tissue polypeptide spe- Tissue polypeptide specific antigen vs tissue polypeptide antigen
cific antigen: y = 0.364 +0.919x; n = 266; r = 0.684; p < 0.001. (TPA-M IRMA): y = 0.037 "4-0.803x; n = 266; r = 0.731;
p < 0.001.
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Fig. 3 Correlation among cytosol levels of the three markers (lin- Tissue polypeptide antigen (TPA IRMA) vs tissue polypeptide anti-
ear regression analysis using In of data). gen (TPA-M IRMA): y = 0.933 + 0.906x; n = 291; r = 0.886;
Linear regression analysis: p < 0.001.
Tissue polypeptide antigen (TPA IRMA) vs tissue polypeptide spe- Tissue polypeptide specific antigen vs tissue polypeptide antigen
cific antigen: y =-0.786 + 1.014x; n = 291; r = 0.810; (TPA-M IRMA): y = 2.50 + 0.73 Ix; ή = 291; r = 0,895;
P < 0.001. p < 0.001.
use of monoclonal antibodies should provide more reli- The results of the present investig tion showed tfaat tis-
able, stable and reproducible assay Systems. ' sue polypeptide antigen (TPA IRMA), tissue polypep-
tide antigen (TPA-M IRMA) and tissue polypeptide spe-
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Fig. 4 Correlation between cytosol and serum levels of each Cytosolic tissue polypeptide specific antigen vs serum tissue poly-
marker (regression analysis using In of data).
Linear regression analysis:
Cytosolic tissue polypeptide antigen (TPA IRMA) vs serum tissue
polypeptide antigen (TPA IRMA): y = 4.806 - 0.134x; n = 144;
r = -0.205; p = 0.014.
peptide specific antigen: y = 4.394 — 0.057x; n = 144;
r = -0.080; p = 0.337.
Cytosolic tissue polypeptide antigen (TPA-M IRMA) vs serum tis-
sue polypeptide antigen (TPA-M IRMA): y = 4.264 - 0.162x;
n = 144; r = -0.176; p = 0.034.
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cific antigen are well correlated both in serum and in
cytosol. The association is closer between tissue poly-
peptide antigen (TPA-M IRMA) and tissue polypeptide
antigen (TPA IRMA) than between the two tissue poly-
peptide antigen and tissue polypeptide specific antigen,
äs could have been expected on the basis of the study
by Bodenmüller et al. on the reactivity of monoclonal
antibodies in the assay kits (18). Although ä good corre-
lation is never proof that the same substance is being
measured, it shoüld be noted that tissue polypeptide spe-
cific antigen measures something that has a close direct
relationship with tissue polypeptide antigen. The similar
association between the three markers and steroid recep-
tors Status, äs well· äs with the [3H]thymidine labelling
index, äs we dempnstrated in a previous study (28),
strongly suggests that tissue polypeptide specific antigen
and tissue polypeptide antigen have Similar meaning
with reference to other biological features of the tumoür.
Accordingly, the diagiiostic sensitivity of the serum
levels of the three markers is remärkably similar.
The association between tissue polypeptide antigen
(TPA-M IRMA) and tuinour bürden (N and T) is too
weak to represent a clinically significant difference be-
tween tissue po^eptide antigen (TPA-M IRMA) and
both tissue polypeptide antigen (TPA IRMA) and tissue
polypeptide specific antigen.
Nevertheless, the fact that the association between tissue
polypeptide antigen and tissue polypeptide specific anti-
gen is more significant in cytosol than .in serum, sug-
gests that factors responsible for the circulating levels of
the marker (such äs the rate of release by the tumoür,
the dilution in body fluids, metabolism and excretion)
may affect the three markers differently, thus supporting
a possible molecular difference between them. The dif-
ferent cytosol-to-serum ratios of the three markers also
support this hypothesis.
Another relevant point is the lack of correlation between
serum and cytosol levels of each marker when measured
in the same patients. This could be due to the effects of
dilution by body fluids, metabolism and excretion on
the serum level of the marker when the tumoür mass
producing the marker is limited, which is the case in
patients bearing primary malignancies. However, apart
frorn any possible Interpretation, it leads to two practical
consequences:
1. the determination of the markers in the two compart-
ments can provide different Information and
2. the determination of the marker in the cytosol is not
predictive of its serum levels, and vice versa.
From the fmdings of the present investigation, we can
draw the following conclusions:
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1. tissue polypeptide antigen (TPA IRMA) and tissue
polypeptide antigen (TPA-M IRMA) provide closely as-
sociated results; although their absolute values are in
part different, they are expected to provide overlapping
clinical Information;
2. tissue polypeptide specific antigen is associated with
tissue polypeptide antigen (TPA-M IRMA) and tissue
polypeptide antigen (TPA IRMA); the relationship be-
tween the tumour markers and other biological quanti-
ties are in the same direction. Even accepting that tissue
polypeptide specific antigen could measure a tissue
polypeptide antigen-specific epitope, it is evident that it
also measures cytokeratin fragments in a quantitatively
significant manner;
3. from a practical point of view, cytosol and serum
should be considered independent biological fluids äs
far äs tissue polypeptide antigen (TPA IRMA) and tissue
polypeptide specific antigen determinations are con-
cerned;
4. the direct association between cytosol levels of tissue
polypeptide antigen (TPA IRMA), tissue polypeptide
antigen (TPA-M IRMA), and tissue polypeptide specific
antigen and receptor Status represents a potential associ-
ation between the mafkers and prognosis, in agreement
with previous fmdings of our group concerning cyto-
solic tissue polypeptide antigen (14—16).
The relationship between the three markef s and the clin-
ical outcome of the patients is the goal of an ongoing
study which should define any actual prognostic role of
tissue polypeptide antigen (TPA-M IRMA) and tissue
polypeptide specific antigen.
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